Updates are available Correction dated 2018-11-13
Click to view Correction: https://doi.org/10.1007/s11912-018-0749-z
-
Authors
Bayan, Claire-Audrey Y.
Lopez, Adriana T.
Gartrell, Robyn D.
Komatsubara, Kimberly M.
Bogardus, Margaret
Rao, Nisha
Chen, Cynthia
Hart, Thomas D.
Enzler, Thomas
Rizk, Emanuelle M.
Pradhan, Jaya Sarin
Marks, Douglas K.
Geskin, Larisa J.
Saenger, Yvonne M.
- License Information
-
More Information
Article History
First Online: 25 August 2018
Change Date: 13 November 2018
Change Type: Correction
Change Details: A correction was made to a sentence in the original article to provide additional clarification in the “Other Oncolytic Viruses” section.
Compliance with Ethical Standards
:
: Claire-Audrey Y. Bayan declares that she has no conflict of interest.Adriana T. Lopez declares that she has no conflict of interest.Robyn D. Gartrell has received compensation from PerkinElmer for service as a consultant, and (with Yvonne M. Saenger, licensed to Columbia University and Amgen) has a patent pending on “Method of Treating Cancer Using Combination BRAF Inhibitor, Talimogene Laherparepvec, and Immune Checkpoint Inhibitor” (U.S. Provisional Application No. 62/410,206).Kimberly M. Komatsubara declares that she has no conflict of interest.Margaret Bogardus declares that she has no conflict of interest.Nisha Rao declares that she has no conflict of interest.Cynthia Chen declares that she has no conflict of interest.Thomas D. Hart declares that he has no conflict of interest.Thomas Enzler declares that he has no conflict of interest.Emanuelle M. Rizk declares that she has no conflict of interest.Jaya Sarin Pradhan declares that she has no conflict of interest.Douglas K. Marks has received compensation from Takeda for service on an advisory board.Larisa J. Geskin declares that she has no conflict of interest.Yvonne M. Saenger has received support through research grants from Amgen to study their oncolytic virus, talimogene laherparepvec; however, Amgen did not support the writing of this article. Along with Robyn D. Gartrell (licensed to Columbia University and Amgen), also has a patent pending on “Method of Treating Cancer Using Combination BRAF Inhibitor, Talimogene Laherparepvec, and Immune Checkpoint Inhibitor” (U.S. Provisional Application No. 62/410,206).
: This article does not contain any studies with human or animal subjects performed by any of the authors.
